SEC Form 4 · accession 0001237899-15-000030
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Landry
Officer — SVP Finance & CFO
Period of report
Apr 8, 2015
Accepted (ET)
Apr 9, 2015 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 8, 2015 | M | 10,000 | $272.70 | A | 15,000 | D | |
| Common Stock | Apr 8, 2015 | F | 6,066 | $449.50 | D | 8,934 | D | |
| Common Stock | Apr 8, 2015 | F | 1,835 | $449.50 | D | 7,099 | D | |
| Common Stock | holding | — | — | — | 35 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $272.70 | Apr 8, 2015 | M | 10,000 | D | — | Sep 9, 2023 | Common Stock | 10,000 | 70,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.